Aller au contenu

Informations médicales indépendantes pour les patients internationaux

Menu

Maladie

Breast cancer

ICD-10 : C50 — Malignant neoplasm of breast

Groupe : Cancers Spécialité : Chirurgie mammaire

Chiffres clés

Valeurs publiées uniquement. Chaque tuile ouvre la section qui porte sa source, son année et sa référence.

Détails de la maladie

Nom anglais
Malignant neoplasm of breast

Également appelé

  • Breast carcinoma

Fourchettes de coûts de traitement

Chaque fourchette ci-dessous est publiée sur une même base de facturation : Avant remboursement. Les sources ne publient aucun chiffre après remboursement ; aucun n'est donc affiché ici.

Parcours de traitement Fourchette de coûts Base du prix Année des données
Chirurgie 18000 – 28430 CNY Forfait par pathologie 2020–2025
Radiothérapie 27000 – 45000 CNY Tarif par acte 2025–2026
Chimiothérapie 6200 – 9000 CNY Forfait par pathologie 2020–2021
Thérapie ciblée 100000 – 195000 CNY Tarif par acte 2025
Immunothérapie 32043 – 42620 CNY Tarif par acte 2024–2025

Les barres partagent une même échelle pour les lignes ci-dessus : chacune commence au chiffre inférieur publié de sa ligne et se termine à son chiffre supérieur. Le chiffre supérieur le plus élevé de cette page est 195000 CNY. Chaque ligne conserve son année de données et sa référence.

5 fourchettes de coûts pour cette maladie, chacune avec sa source sur la page de la ligne.

Les valeurs rédigées en chinois sont citées telles que publiées par la source.

Voir toutes les fourchettes de coûts →

Survie à cinq ans

Taux de survie à 5 ans 80.9% IC à 95 % 80.5–81.3

Population
Global (tous stades confondus) · Survie relative standardisée selon l’âge
Période
2019–2021
Éditeur
Centre national du cancer
Nature de la valeur
Valeur estimée (analyse hybride)
Périmètre du registre
281 registres du cancer de population
Disponibilité des données par stade
Non publié

Les valeurs rédigées en chinois sont citées telles que publiées par la source.

Voir tous les taux de survie →

Comment lire ce chiffre. Ce chiffre est publié pour tous les stades confondus ; il s'agit donc d'une moyenne sur l'ensemble des personnes des données du registre national, non d'un pronostic pour une personne. Pour la plupart des cancers, le stade au diagnostic est le facteur unique le plus fort des différences de survie : la survie est généralement plus élevée lorsque le cancer est détecté à un stade précoce et plus faible lorsqu'il est détecté plus tard. Les comparaisons entre cancers dépendent aussi de la précocité ou de la tardiveté à laquelle chacun tend à être diagnostiqué ; un chiffre plus bas ne signifie donc pas en soi des soins moins bons.

Le chiffre est une survie relative : il compare les personnes diagnostiquées avec ce cancer à des personnes du même âge et du même sexe dans la population générale, et il est standardisé selon l'âge ; ce n'est donc pas la part de patients encore vivants après cinq ans. Il est publié comme valeur estimée (analyse hybride) car les rapports des registres arrivent avec un décalage ; le Centre national du cancer a donc modélisé la période la plus récente. Pour situer, la même source publie une survie relative à cinq ans de 43,7 % pour l'ensemble des cancers en 2019–2021.

Hôpitaux disposant d'un dossier publié pour cette maladie

Sélectionnés à partir de sources de données publiques officielles

Ces hôpitaux sont sélectionnés à partir de sources de données publiques officielles — les classements de réputation par spécialité de l'université Fudan, la liste des spécialités cliniques clés nationales et les centres nationaux de recherche clinique — afin que chaque ligne d'une fiche puisse être vérifiée dans sa source publiée. Il ne s'agit pas d'une inscription payante ou promue.

Comment ces hôpitaux ont été sélectionnés

Admission. Un hôpital est listé pour une maladie lorsque la spécialité à laquelle cette maladie est rattachée porte au moins l'un des éléments suivants : une place ou une nomination dans le classement de réputation par spécialité de l'université Fudan ; un titre de spécialité clinique clé nationale de niveau A, B ou C ; ou un centre national de recherche clinique ou un laboratoire clé d'État dans cette spécialité. L'accréditation JCI est affichée comme un badge ; elle ne détermine jamais l'admission et ne détermine jamais l'ordre.

Ordre. Étape 1 : une place Fudan entre 1 et 10 pour la spécialité. Étape 2 : une autre place Fudan, ou une nomination. Étape 3 : un titre de spécialité clinique clé nationale de niveau A. Étape 4 : un titre de spécialité clinique clé nationale de niveau B. Étape 5 : un centre national de recherche clinique ou un laboratoire clé d'État dans la spécialité, un centre avant un laboratoire. Étape 6 : un titre de spécialité clinique clé nationale de niveau C, qui est un enregistrement que nous publions sans source officielle indépendante et qui figure donc après les autres.

Égalités. Au sein d'une même étape : la meilleure place Fudan d'abord, puis le niveau de spécialité clé le plus fort (A avant B avant C), puis la province, puis la ville, puis le nom de l'hôpital — le même ordre province-ville-nom que celui utilisé par le répertoire des hôpitaux. Huit hôpitaux au maximum sont listés.

Lorsque la liste est courte. Cinq hôpitaux ou plus : les huit premiers sont listés. Trois ou quatre : tous sont listés, et un volet supplémentaire ajoute les autres enregistrements jusqu'à huit, chacun portant son niveau de preuve. Un ou deux : de même, avec ce volet ouvert et une ligne indiquant combien d'hôpitaux disposent d'un dossier public solide. Aucun : la page indique qu'aucun dossier public solide n'a été trouvé et renvoie au répertoire de la spécialité. Une place, un établissement ou un décompte ne sont jamais inventés pour remplir la liste.

Les classements Fudan sont le classement de réputation par spécialité le plus largement reconnu par les cliniciens chinois, publié chaque année par l'institut de gestion hospitalière de l'université Fudan.

  1. West China Hospital, Sichuan University

    Chengdu

    Spécialité clinique clé nationale

    Également classé : Chirurgie générale #3, Chirurgie thoracique #4, Urologie #2 (ex æquo) dans la liste Fudan.

  2. Qilu Hospital of Shandong University

    Jinan

    Spécialité clinique clé nationale

    Recherches publiées

    3 études publiées supplémentaires

    PubMed indexe 5 articles sur cette maladie qui nomment cet hôpital.

    Également classé : Gynécologie #7 (ex æquo), Oto-rhino-laryngologie nommé, Gastro-entérologie nommé dans la liste Fudan.

  3. Shandong Cancer Hospital

    Jinan

    Spécialité clinique clé nationale

  4. Hubei Cancer Hospital

    Wuhan

    Spécialité clinique clé nationale

    Recherches publiées

    3 études publiées supplémentaires

    PubMed indexe 5 articles sur cette maladie qui nomment cet hôpital.

  5. Hunan Cancer Hospital

    Changsha

    Spécialité clinique clé nationale

    Recherches publiées

    PubMed indexe 1 article sur cette maladie qui nomme cet hôpital.

    Également classé : Oncologie médicale nommé dans la liste Fudan.

Essais cliniques (traitements expérimentaux)

En complément des soins standards, des études de recherche clinique sur Breast cancer peuvent actuellement être ouvertes aux participants en Chine. Les traitements à l'étude n'ont pas été approuvés par le régulateur comme traitement standard — il s'agit de recherche clinique, non de soins courants. Chaque fiche nomme l'investigateur principal et l'hôpital qui mène l'étude. Si cela vous intéresse, contactez l'hôpital pour vous renseigner sur l'éligibilité et décider vous-même de candidater.

  1. Étude To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients: A Prospective, Multicenter, Non-interventionist Real World Study

    Hôpital
    Henan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06605521

  2. Étude Integrated PET/MRI Study of Cognitive Impairment in Premenopausal Breast Cancer Patients After Chemotherapy or Endocrine Therapy

    Statut
    En recrutement
    Registre
    NCT05305092

  3. Étude The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery: an Observational Cohort Study

    Investigateur principal
    Chen Kai · Clinical Professor
    Hôpital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Statut
    En recrutement
    Registre
    NCT06425874

  4. Étude Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

    Hôpital
    Tianjin Medical University Cancer Institute & Hospital
    Statut
    En recrutement
    Registre
    NCT07372079

  5. Étude Clinical Study of 18F-Labeled FAPI-04 in PET Imaging of Breast Cancer

    Hôpital
    The Affiliated Hospital of Qingdao University
    Statut
    En recrutement
    Registre
    NCT06916338
126 études enregistrées supplémentaires

  1. Étude Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Stage II-III HER2-positive Breast Cancer Patients Who Have Poor Outcomes After Treatment With Trastuzumab and Pertuzumab

    Investigateur principal
    Caigang Liu · Director
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT04983121

  2. Étude Effect of Circulating Tumor Cell Detection in Patients With Luminal A Breast Cancer Without Lymph Node Metastasis Instead of Conventional Imaging Examination After Operation: a Non-Inferiority Randomized Controlled Clinical Trial

    Investigateur principal
    Jianyi Li · Principal Investigator
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT04065321

  3. Étude A Phase II Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

    Investigateur principal
    Caigang Liu · Director of the Cancer Center
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT05635487

  4. Étude VERITAS Longitudinal Real-world Registry of HR+/HER2- mBC to Understand Treatment Pattern and Clinical Outcomes in HR+/HER2- mBC

    Hôpital
    Jiangsu Province Hospital
    Statut
    En recrutement
    Registre
    NCT07743944

  5. Étude A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.

    Hôpital
    Anhui Provincial Hospital
    Statut
    En recrutement
    Registre
    NCT05872347

  6. Étude Application of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in All-Scenario Breast Cancer Radiotherapy: A Prospective Clinical Study

    Investigateur principal
    Xiaoli Yu · Professor
    Hôpital
    Fudan University Shanghai Cancer Center
    Statut
    En recrutement
    Registre
    NCT07776301

  7. Étude A Cohort Study of Adjuvant Therapy With Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer

    Investigateur principal
    Shu Wang · director of breast center
    Hôpital
    Peking University People's Hospital
    Statut
    En recrutement
    Registre
    NCT06711055

  8. Étude Neoadjuvant Therapy Study Guided by Drug Screening in Vitro Patient-derived Tumor-like Cell Clusters for HER2 Positive Early Breast Cancer Patients

    Hôpital
    Peking University People's Hospital
    Statut
    En recrutement
    Registre
    NCT04750122

  9. Étude Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial

    Statut
    En recrutement
    Registre
    NCT06938360

  10. Étude A Single-arm, Prospective Phase II Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer (TNBC)

    Investigateur principal
    Shuangyue Liu · Clinical Professor
    Hôpital
    West China Hospital, Sichuan University
    Statut
    En recrutement
    Registre
    NCT05447702

  11. Étude Application of Radiomics in Correlation Between Ultrasound Characteristics and Pathological Prognostic Factors in Breast Cancer

    Hôpital
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Statut
    En recrutement
    Registre
    NCT04483804

  12. Étude Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer

    Hôpital
    The Second Affiliated Hospital Zhejiang University School of Medicine
    Statut
    En recrutement
    Registre
    NCT07616440

  13. Étude Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05): A Prospective, Single-arm, Multi-center Clinical Study

    Hôpital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Statut
    En recrutement
    Registre
    NCT06832904

  14. Étude Safety and Feasibility of Irreversible Electroporation for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study

    Investigateur principal
    Tian'an Jiang · Chief Physician
    Hôpital
    The First Affiliated Hospital, Zhejiang University School of Medicine
    Statut
    En recrutement
    Registre
    NCT07263451

  15. Étude Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) for Chronic Insomnia in Breast Cancer Survivors, A Randomized Controlled Trial

    Investigateur principal
    Jing MA · Pro.
    Hôpital
    Peking University First Hospital
    Statut
    En recrutement
    Registre
    NCT05813392

  16. Étude Impact of Erector Spinae Plane Block With Adjuvant Dexmedetomidine on Chronic Postsurgical Pain in Breast Cancer Patients: a Two-center Randomized Controlled Trial

    Investigateur principal
    Dong-Xin Wang · Professor
    Hôpital
    Peking University First Hospital
    Statut
    En recrutement
    Registre
    NCT05494502

  17. Étude A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of GB491 in Combination With Letrozole in Subjects With HR Positive and HER2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received Systemic Therapy in This Disease Setting

    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT05851014

  18. Étude A Phase III, Multicenter, Open-label, Randomized Controlled Study Comparing GQ1005 and Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and a Taxane

    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT07673029

  19. Étude A Real-World Observational Study on Post-Resistance Treatment Outcomes in Advanced Breast Cancer Patients After CDK4/6 Inhibitors, PIK3CA Inhibitors, or Trastuzumab Deruxtecan Therapy

    Hôpital
    Hunan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT07073755

  20. Étude A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of Anlotinib-based Combination Therapy in Hormone Receptor-positive Metastatic Breast Cancer Resistant to CDK4/6is.

    Hôpital
    Hunan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06734533

  21. Étude A Prospective, Multigroup, Multi-center, Open-label Clinical Study of Trastuzumab Rezetecan as Neoadjuvant Therapy Combined With Toripalimab in HR+/HER2-low Breast Cancer Patients (NEOTORCH-BREAST 08)

    Hôpital
    Third Affiliated Hospital of Harbin Medical University
    Statut
    En recrutement
    Registre
    NCT07383818

  22. Étude A Randomized, Multi-center, Open-label, Phase III Trial of Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Metastatic Breast Cancer (FAMILY)

    Investigateur principal
    Herui Yao · Principal Investigator
    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    En recrutement
    Registre
    NCT04263298

  23. Étude A Randomized, Open-label, Multicenter Study Comparing Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

    Hôpital
    Fujian Medical University Union Hospital
    Statut
    En recrutement
    Registre
    NCT05292742

  24. Étude Trastuzumab Combined With Pyrotinib and Chemotherapy for Locally Advanced, Inflammatory, or Early HER2-positive Mammary glandsCancer: One Arm, Open, Phase II Clinical Study

    Investigateur principal
    Tao OUYANG · Chairman of Breast Center of Peking University Cancer Hospital
    Hôpital
    Peking University Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT04481932

  25. Étude Intraoperative Nomogram to Predict Breast Cancer- Related Lymphedema Based in Artificial Intelligence Image Recognition: a Randomized Controlled Trial

    Investigateur principal
    Gaosong Wu, Ph D, MD · Director
    Hôpital
    Zhongnan Hospital of Wuhan University
    Statut
    En recrutement
    Registre
    NCT04665882

  26. Étude A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

    Hôpital
    Peking University Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06120283

  27. Étude A Randomized Controlled, Open-label, Multicenter Clinical Study of Pyrotinib Maleate Combined With Trastuzumab,Dalpiciclib, and Letrozole Versus Trastuzumab Combined With Pertuzumab, Docetaxel, and Carboplatin as Neoadjuvant Therapy for Stage II-III HR +/HER2 + Breast Cancer

    Investigateur principal
    Caigang Liu · Professor
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT05638594

  28. Étude Evaluation of Axillary Lymph Nodes Using Prone Positioning Computed Tomography Scan and Ultrasound in Patients With Breast Cancer

    Investigateur principal
    Jianyi Li · Principal Investigator
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT05346510

  29. Étude A Phase II, Multicenter, Open-Label Neoadjuvant Study to Evaluate the Safety and Efficacy of Disitamab Vedotin in Combination With Pertuzumab With or Without Toripalimab for HER2 Positive Breast Cancer

    Hôpital
    Fudan University Shanghai Cancer Center
    Statut
    En recrutement
    Registre
    NCT06178159

  30. Étude Effect of Neoadjuvant Radiation and Prediction of Response to Treatment in Locally Advanced Breast Cancer

    Investigateur principal
    Xiaoli Yu · Professor
    Hôpital
    Fudan University Shanghai Cancer Center
    Statut
    En recrutement
    Registre
    NCT05479409

  31. Étude A Cohort Study of Different Choice of Adjuvant Therapy in Non-PCR Patients With HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

    Investigateur principal
    Shu Wang · director of breast center
    Hôpital
    Peking University People's Hospital
    Statut
    En recrutement
    Registre
    NCT06693037

  32. Étude A Single-center, Single-arm, Open Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery

    Statut
    En recrutement
    Registre
    NCT07071402

  33. Étude Research on the Potential Mechanisms Underlying the Efficacy Differences in Specific Neoadjuvant Treatment Regimens for Different Subtypes of Breast Cancer

    Statut
    En recrutement
    Registre
    NCT07012720

  34. Étude A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

    Hôpital
    Beijing Hospital
    Statut
    En recrutement
    Registre
    NCT05950945

  35. Étude Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression

    Hôpital
    Xiangya Hospital of Central South University
    Statut
    En recrutement
    Registre
    NCT06938373

  36. Étude A Multicenter, Phase III, Randomized Controlled Trial Comparing Camrelizumab Plus Apatinib and Eribulin Versus Physician's Choice Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer

    Investigateur principal
    Jieqiong Liu, M.D., Ph.D. · Professor
    Hôpital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Statut
    En recrutement
    Registre
    NCT06889688

  37. Étude Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer (TAYLOR-003)

    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT07616427

  38. Étude A Randomized, Open-label, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in Patients With HER2-positive Advanced Breast Cancer

    Hôpital
    The First Affiliated Hospital of Anhui Medical University
    Statut
    En recrutement
    Registre
    NCT07008976

  39. Étude Monitoring Circulating Tumor DNA in Patients With Early Stage Breast Cancer

    Statut
    En recrutement
    Registre
    NCT04353557

  40. Étude A Prospective, Randomized Controlled Phase II Trial Investigating the Optimal Timing of Antibody Drug Conjugates in Advanced HER2-Negative Breast Cancer Patients

    Investigateur principal
    Tao Sun · Principal Investigator
    Hôpital
    Liaoning Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT07657130

  41. Étude A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Ivonescimab Neoadjuvant Therapy for Luminal-type Breast Cancer

    Investigateur principal
    HAN GUANG · professor
    Hôpital
    Hubei Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06402435

  42. Étude A Single-arm, Open, Phase II Clinical Study of SBRT, Chemotherapy, and Cadonilimab (AK104) Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

    Investigateur principal
    HAN GUANG · professor
    Hôpital
    Hubei Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06401005

  43. Étude Gut Microbiota Changes in Breast Cancer Patients Treated With Pyrotinib and Correlation With Drug-Induced Diarrhea: An Observational Cohort Study

    Investigateur principal
    Xinhong Wu, PhD · vice-president
    Hôpital
    Hubei Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT07264985

  44. Étude Large Segmentation Radiotherapy±Deep Inspiratory Breath Hold for Left Sided Breast Cancer, A Real-World Study

    Hôpital
    Peking Union Medical College Hospital
    Statut
    En recrutement
    Registre
    NCT06660628

  45. Étude Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

    Hôpital
    Peking Union Medical College Hospital
    Statut
    En recrutement
    Registre
    NCT06411678

  46. Étude A Single-center, Blinded, Efficacious, Phase III Randomized Clinical Trial Initiated by Investigators to Investigate the Use of Surface Guided Radiation Therapy (SGRT) in Combination With Deep Inspiration Breath Hold (DIBH) Technique for Left Breast Cancer Treatment, Compared to Traditional Laser Alignment With Free Breathing Treatment

    Hôpital
    Peking Union Medical College Hospital
    Statut
    En recrutement
    Registre
    NCT05804916

  47. Étude Effect of Huaier Granule on Postoperative Adjuvant Treatment for High-risk Early-stage Triple-negative Invasive Ductal Carcinoma: a Prospective, Multicenter, Randomized, Controlled, Open-label Study

    Investigateur principal
    Zhimin Shao · Professor
    Hôpital
    The First Affiliated Hospital of Anhui Medical University
    Statut
    En recrutement
    Registre
    NCT04790305

  48. Étude Surveillance of Circulating Tumor Cell Phenotype in Early Stage Breast Cancer Patients With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy

    Hôpital
    Hunan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT05326295

  49. Étude A Single-arm, Multicenter, Open-labeled Clinical Study of UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

    Hôpital
    Hunan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT05535413

  50. Étude A Clinical Study of Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR Positive HER2 Positive Breast Cancer

    Hôpital
    Henan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06276868

  51. Étude Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer: a Prospective, Multicenter, Single Arm, Real World Study

    Hôpital
    Henan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06518135

  52. Étude A Single-arm, Prospective, Open-label Phase II Clinical Study of Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer

    Hôpital
    Henan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT05398861

  53. Étude Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

    Investigateur principal
    Zhenzhen Liu · Professor
    Hôpital
    Henan Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06860529

  54. Étude Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With HER2 Negative Metastatic Breast Cancer Treated With Sacituzumab Govitecan: A Retrospective Trial in China（SACIT-OUT）

    Investigateur principal
    Wang Xiaojia · MD
    Hôpital
    Zhejiang Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06784921

  55. Étude A Phase II, Randomised, Open-label, Multicentre Study of Posaconazole Plus PD-1 Inhibitors and Chemotherapy Versus PD-1 Inhibitors and Chemotherapy as Neoadjuvant Therapy for Triple Negative Breast Cancer

    Investigateur principal
    Yongsheng Wang · Professor
    Hôpital
    Shandong Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT06802757

  56. Étude Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

    Hôpital
    Sir Run Run Shaw Hospital Affiliated with Zhejiang University School of Medicine
    Statut
    En recrutement
    Registre
    NCT06977893

  57. Étude A Multi-center Prospective Observational Study to Assess the Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

    Hôpital
    China-Japan Friendship Hospital
    Statut
    En recrutement
    Registre
    NCT06210776

  58. Étude Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating

    Investigateur principal
    Yong Yang · Chief physician
    Hôpital
    Fujian Medical University Union Hospital
    Statut
    En recrutement
    Registre
    NCT05704166

  59. Étude Internal Mammary Lymph Nodes Irradiation in High-risk Breast Cancer After Neoadjuvant Chemotherapy: a Phase III Randomized, Controlled Clinical Trial

    Investigateur principal
    Yong Yang · M.D.
    Hôpital
    Fujian Medical University Union Hospital
    Statut
    En recrutement
    Registre
    NCT06559696

  60. Étude A Randomized, Open-label, Parallel-controlled, Multicenter Phase III Clinical Study Evaluating TQB2930 Combined With Investigator's Choice of Chemotherapy Versus Trastuzumab Combined With Investigator's Choice of Chemotherapy in the Treatment of HER2-Positive Advanced Breast Cancer

    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT07047365

  61. Étude Efficacy and Safety of Probiotics Versus Standard Care in Preventing Diarrhea Induced by Neratinib in Breast Cancer Patients: A Prospective Randomized Controlled Clinical Trial

    Hôpital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Statut
    En recrutement
    Registre
    NCT06892093

  62. Étude Disitamab Vedotin in Combination With Pyrotinib Versus THP in the First-line Treatment for HER2-positive Advanced Breast Cancer, a Multicentre, Randomized, Double-blind Controlled, Phase III Trial

    Hôpital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Statut
    En recrutement
    Registre
    NCT06278870

  63. Étude Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

    Hôpital
    The Affiliated Hospital of Qingdao University
    Statut
    En recrutement
    Registre
    NCT06916637

  64. Étude A Non-interventional Study to Evaluate the Effectiveness and Safety of Inavolisib in Patients With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer (reaINAVO)

    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT07347600

  65. Étude An Interventional, Multicenter Study of Trastuzumab Rezetecan as Neoadjuvant Therapy in Patients With THP-Insensitive HER2-Positive Early Breast Cancer

    Investigateur principal
    Hao Zhou · Associate Chief Physician
    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT07647263

  66. Étude Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial

    Investigateur principal
    Caigang Liu · Principal Investigator
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT04137653

  67. Étude The Association of Psychological Stress with the Efficacy of Neoadjuvant Therapy in Breast Cancer

    Investigateur principal
    Caigang Liu · Director of oncology
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT06690645

  68. Étude The Efficiency for Patient With Stage II-III HR+/HER2+ Early Breast Cancer With Standard Neoadjuvant Therapy: a Retrospective, Multicenter Study in Real World Settings.

    Investigateur principal
    Caigang Liu · Professor
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT05263570

  69. Étude Albumin-bound Paclitaxel Combined With Carboplatin Versus Epirubicin Combined With Docetaxel as Neoadjuvant Therapy for Triple-negative Breast Cancer: a Multicenter Randomized Controlled Phase IV Clinical Trial

    Investigateur principal
    Caigang Liu · Principal Investigator
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT04136782

  70. Étude The Association Between Plasma Metabolites and the Risk, Efficacy and Prognosis in Early Breast Cancer

    Investigateur principal
    Caigang Liu · director of oncology
    Hôpital
    Shengjing Hospital
    Statut
    En recrutement
    Registre
    NCT06698679

  71. Étude A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT06827236

  72. Étude A Phase II, Open-Label, Multicenter Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of TT-00420 (Tinengotinib) Tablets Combined With Fulvestrant Injection in Patients With Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER-2) Negative or Low-Expressing Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment

    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    En recrutement
    Registre
    NCT07498478

  73. Étude Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial

    Investigateur principal
    Zhong-yu Yuan · Clinical Professor
    Hôpital
    Sun Yat-sen University Cancer Center
    Statut
    En recrutement
    Registre
    NCT04722978

  74. Étude A Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer: A Prospective Randomized Controlled Trial

    Investigateur principal
    Kun Wang · Clinical Professor
    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    En recrutement
    Registre
    NCT07352930

  75. Étude A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients

    Investigateur principal
    Kun Wang · Professor
    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    En recrutement
    Registre
    NCT06811870

  76. Étude Clinical Cohort Study of 21-gene Assay in Predicting the Prognosis of Elder Luminal-A Breast Cancer Patients With Axillary Lymph Node Metastasis

    Hôpital
    Qilu Hospital of Shandong University
    Statut
    En recrutement
    Registre
    NCT06891651

  77. Étude Prospective, One-arm, Phase II Clinical Study of Ivoximab Combined With TROP2 ADC in the Treatment of Brain Metastases in Triple-negative Breast Cancer

    Investigateur principal
    Jian Zhang,MD · Director of Phase I clinical Research ward
    Hôpital
    Fudan University Shanghai Cancer Center
    Statut
    En recrutement
    Registre
    NCT06793332

  78. Étude Evaluating Safety and Efficacy of INtrathecal or Ommaya ReserVoir Administration of T-DXd in Patients With HER2-Expressing Breast Cancer With Active Leptomeningeal and/or Brain Metastases Based on Systemic Therapy: Phase I/II Study

    Investigateur principal
    Jian Zhang,MD · Director of Phase I Clinical Trial Department; Professor, Chief physician of oncology department
    Hôpital
    Fudan University Shanghai Cancer Center
    Statut
    En recrutement
    Registre
    NCT07134153

  79. Étude A Prospective, Randomized, Open-label Phase III Clinical Study of the Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy Versus Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

    Investigateur principal
    Zhimin Shao · Chief Physician
    Hôpital
    Peking University Cancer Hospital
    Statut
    En recrutement
    Registre
    NCT05891093

  80. Étude Cohort Study of Adjuvant Chemotherapy Combined With Targeted Therapy for Intermediate Risk HER2 Positive and Lymph Node Negative Early Breast Cancer

    Investigateur principal
    Shu Wang · director of breast center
    Hôpital
    Peking University People's Hospital
    Statut
    En recrutement
    Registre
    NCT06711068

  81. Étude A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy

    Hôpital
    Cancer Hospital of Chinese Academy of Medical Sciences
    Statut
    En recrutement
    Registre
    NCT07679360

  82. Étude IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment

    Hôpital
    Anhui Provincial Hospital
    Statut
    En recrutement
    Registre
    NCT06926868

  83. Étude A Randomized Controlled Phase II/III Clinical Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT06891833

  84. Étude A Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression

    Hôpital
    First Affiliated Hospital of Guangzhou Medical University
    Statut
    En recrutement
    Registre
    NCT07043725

  85. Étude The Safety and Efficacy of IMPT or IMRT for Breast Cancer: A Prospective Observational Study

    Investigateur principal
    JIAYI CHEN · Chair of Radiation Oncology Department
    Hôpital
    Ruijin Hospital
    Statut
    En recrutement
    Registre
    NCT06826885

  86. Étude Prospective Randomized Controlled Study on Precision Irradiation of Regional Lymph Node for Clinical High-risk pN0 Breast Cancer

    Investigateur principal
    JIAYI CHEN · Prof
    Hôpital
    Ruijin Hospital
    Statut
    En recrutement
    Registre
    NCT05976412

  87. Étude Early Prediction and Warning for Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy: a Prospective, Multicenter, Clinical Trial

    Investigateur principal
    Chunyan Ma · Chief of Cardiovascular Ultrasound
    Hôpital
    First Hospital of China Medical University
    Statut
    En recrutement
    Registre
    NCT06282796

  88. Étude A Phase 2 Trial of SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

    Investigateur principal
    Min Yan, MD · Chief physician
    Hôpital
    Henan Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07125950

  89. Étude Sensitivity and Specificity of Ultrasound-Guided Core Needle Biopsy in Evaluating Axillary Lymph Node Metastasis in Breast Cancer

    Investigateur principal
    Dezhi Zhang · Principal Investigator (PI)
    Hôpital
    The First Hospital of Jilin University
    Statut
    Pas encore en recrutement
    Registre
    NCT07573657

  90. Étude A Multicenter, Randomized, Controlled, Open Label Clinical Study on the Treatment of Recurrent or Metastatic Triple Negative Breast Cancer With Cadonilimab Combined With Eribulin Versus Eribulin Alone

    Investigateur principal
    Caigang Liu · Postdoctoral, Chief Physician
    Hôpital
    Shengjing Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT06202313

  91. Étude An Open-label, Randomized, Multi-center, Multi-cohort Clinical Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

    Investigateur principal
    Caigang Liu · Shengjing Hospital
    Hôpital
    Shengjing Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07101614

  92. Étude A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients

    Investigateur principal
    Kun Wang · PhD
    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT06825975

  93. Étude A Phase 2, Single Arm Study Investigating the Use of Chidamide and PD-1 Antibody Combination With Anlotinib in HER2-low, Unresectable and/or Metastatic Breast Cancer

    Investigateur principal
    Kun Wang · Professor
    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT06547476

  94. Étude Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer After Trastuzumab Deruxtecan Resistance:A Single-Arm, Multicenter, Exploratory Clinical Study

    Statut
    Pas encore en recrutement
    Registre
    NCT07333937

  95. Étude Tolerability of Dalpiciclib Versus Abemaciclib/Ribociclib in Combination With Standard Endocrine Therapy for HR-Positive/HER2-Negative Early Breast Cancer: A Prospective, Multicenter, Randomized Controlled Trial

    Investigateur principal
    Zhenzhen Liu · Professor
    Hôpital
    Henan Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07706933

  96. Étude A Multicenter, Prospective, Randomized Two-arm Controlled Trial Comparing the Impact of Robotic Versus Endoscopic Surgery on Breast Nerve Function Following Nipple-sparing Mastectomy for Breast Cancer

    Investigateur principal
    haiyanli · Chief Physician, Department of Breast Surgery
    Hôpital
    Guangzhou Women and Children's Medical Center
    Statut
    Pas encore en recrutement
    Registre
    NCT07850154

  97. Étude Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

    Hôpital
    The First Hospital of Jilin University
    Statut
    Pas encore en recrutement
    Registre
    NCT06868017

  98. Étude Efficacy and Safety of SHR-A1811 Versus Pyrotinib Plus Capecitabine in Patients With Trastuzumab Primary-Resistant HER2-Positive Advanced Breast Cancer：A Prospective, Multicenter, Open-Label, Randomized, Controlled Study

    Investigateur principal
    Hanfang Jiang, MD · Professor
    Hôpital
    Peking University Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07417241

  99. Étude A Clinical Model Based on Dynamic Changes in Anti-Müllerian Hormone to Predict Ovarian Reserve in Perimenopausal Breast Cancer Patients

    Investigateur principal
    Jianyi Li · Chief Physician
    Hôpital
    Shengjing Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07497191

  100. Étude Trastuzumab Combined With Pertuzumab and Sequential Use of Pyrotinib vs. Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy

    Investigateur principal
    Caigang Liu · Director
    Hôpital
    Shengjing Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT04973319

  101. Étude Fasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer

    Investigateur principal
    Kun Wang · Professor
    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07077018

  102. Étude A Prospective Study to Evaluate the Clinical Significance of Medical Humanities-based Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage

    Investigateur principal
    Jiong Wu · Principal Investigator
    Hôpital
    Fudan University Shanghai Cancer Center
    Statut
    Pas encore en recrutement
    Registre
    NCT06965556

  103. Étude 针刺治疗激素受体阳性乳腺癌患者潮热的随机对照试验研究，A Randomized Controlled Trial of Acupuncture for the Management of Hot Flashes in Patients With Hormone Receptor-Positive Breast Cancer

    Investigateur principal
    Shu Wang · director of breast center
    Hôpital
    Peking University People's Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07294339

  104. Étude A Multicenter, Single-Arm, Open-Label Study of Extended Sentinel Lymph Node Biopsy Using Methylene Blue as a Single Tracer After Neoadjuvant Therapy in Patients With Axillary Node-Positive Breast Cancer

    Statut
    Pas encore en recrutement
    Registre
    NCT07532096

  105. Étude SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases

    Hôpital
    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Statut
    Pas encore en recrutement
    Registre
    NCT06975475

  106. Étude Effect of Continuous Intraoperative Esketamine Infusion on Perioperative Negative Emotions in Breast Cancer Surgery Patients With Mild-to-Severe Depression: A Randomized Controlled Trial

    Investigateur principal
    Weidong Mi · Director (Cheif expert of National key research and development program of China 2018YFC2001900)
    Hôpital
    Chinese PLA General Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07374198

  107. Étude Effects of Acupuncture for Anxiety and/or Depression Among Patients With Breast Cancer

    Investigateur principal
    Yuanjie Sun · Attending physician
    Hôpital
    Guang'anmen Hospital of China Academy of Chinese Medical Sciences
    Statut
    Pas encore en recrutement
    Registre
    NCT07183813

  108. Étude Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer: A Historical Cohort Study

    Hôpital
    Zhejiang Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07188116

  109. Étude A Prospective Clinical Study Evaluating Bemotuzumab Combined With Chemotherapy to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

    Investigateur principal
    Xuli Meng · Chief physician
    Hôpital
    Zhejiang Provincial People's Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT06975644

  110. Étude A Phase Ib, Open-label, Modular Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors

    Hôpital
    Hunan Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07163481

  111. Étude The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.

    Investigateur principal
    Wang Xiaojia · chief physician
    Hôpital
    Zhejiang Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT06140576

  112. Étude A Prospective and Multicenter Clinical Study to Identify the Molecular Characterization and Subtypes in Patients With HER2-positive Breast Cancer Receiving Neoadjuvant Trastuzumab and Pertuzumab.

    Investigateur principal
    Jinming Yu · PhD, MD
    Hôpital
    Shandong Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07187752

  113. Étude Efficacy and Safety of Pedicled Lateral Chest Wall Lymph-Adipofascial Flap Axillary Reconstruction for the Prevention of Breast Cancer-Related Arm Lymphedema: A Prospective, Single-Arm, Phase II Clinical Study

    Hôpital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Statut
    Pas encore en recrutement
    Registre
    NCT07415200

  114. Étude A Multicenter, Prospective Phase II Single-arm Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with T-DXd in Combination with an Immune Checkpoint Inhibitor in HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer

    Investigateur principal
    Huijin Wang · Director of Thyroid and Breast Disease Center
    Hôpital
    Guangzhou Women and Children's Medical Center
    Statut
    Pas encore en recrutement
    Registre
    NCT06733233

  115. Étude Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3126 in Subjects With Breast Cancer

    Hôpital
    Sun Yat-sen Memorial Hospital, Sun Yat-sen University
    Statut
    Pas encore en recrutement
    Registre
    NCT07697443

  116. Étude A Two-cohort Study of SHR-A1811 in the Treatment of HER2-positive Breast Cancer With Brain Metastases, With or Without Leptomeningeal Metastases.

    Hôpital
    Peking University Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07177950

  117. Étude A Prospective, Double-Arm Study on the Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging

    Investigateur principal
    xuliang · professor
    Hôpital
    Peking University Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07527806

  118. Étude Prospective Evaluation of Sentinel Lymph Node Biopsy Combined With Wire Localized Lymph Node Biopsy for Omitting Axillary Lymph Node Dissection in Breast Cancer Patients With 1-2 Sonographically Abnormal Lymph Nodes: A Diagnostic Study

    Hôpital
    Peking University Cancer Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07791771

  119. Étude Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes (HS-IT101) for the Treatment of Advanced Breast Cancer

    Hôpital
    The Affiliated Hospital of Qingdao University
    Statut
    Pas encore en recrutement
    Registre
    NCT05505812

  120. Étude A Single-Center Retrospective Study to Develop a Nomogram for Predicting Recurrence in HR+/HER2- Early Breast Cancer Using Real-World Data

    Investigateur principal
    Jianyi Li · Principal Investigator
    Hôpital
    Shengjing Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07484763

  121. Étude An Exploration of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery

    Investigateur principal
    Kun Wang · Professor
    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT06811857

  122. Étude A Multicenter, Randomized, Open-Label, Controlled Phase II Clinical Study of Paclitaxel Polymeric Micelles Combined With Trastuzumab and Pertuzumab (HP) and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer

    Investigateur principal
    Jian Zhang,MD · Director of Phase I Unit，Chief physician of oncology department
    Hôpital
    Fudan University Shanghai Cancer Center
    Statut
    Pas encore en recrutement
    Registre
    NCT07581795

  123. Étude A Multicenter, Prospective, Randomized Phase II Trial Evaluating Trastuzumab, Pertuzumab, Docetaxel Combined With QL1706 Versus Combined With Carboplatin as Neoadjuvant Therapy for Early or Locally Advanced HER2+ Breast Cancer

    Hôpital
    Guangdong Provincial People's Hospital
    Statut
    Pas encore en recrutement
    Registre
    NCT07246317

  124. Étude Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

    Investigateur principal
    Yingying Xu · Professor
    Hôpital
    First Hospital of China Medical University
    Statut
    Pas encore en recrutement
    Registre
    NCT07305246

  125. Étude TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer

    Investigateur principal
    Yingying Xu · Professor
    Hôpital
    First Hospital of China Medical University
    Statut
    Pas encore en recrutement
    Registre
    NCT07271992

  126. Étude Effect of Intraoperative Transcutaneous Auricular Vagus Nerve Stimulation on Perioperative Negative Emotions in Patients Undergoing Breast Cancer Surgery: A Multicenter, Randomized, Double-Blind, Sham-Controlled Trial

    Investigateur principal
    Weidong Mi · Director (Cheif expert of National key research and development program of China 2018YFC2001900)
    Hôpital
    Beijing Tiantan Hospital, Capital Medical University
    Statut
    Pas encore en recrutement
    Registre
    NCT07458646

Cette page ne partage que des informations d'études publiquement enregistrées. Elle ne recommande ni n'encourage la participation à une étude. La participation est entièrement volontaire et les risques d'un traitement non approuvé sont inconnus ; contactez directement l'hôpital pour les critères d'éligibilité et les détails du consentement éclairé.

Thérapies avancées : ce qui est autorisé et ce qui est en essai

Hôpitaux disposant d'un titre de spécialité clé nationale

Afficher les fiches des hôpitaux 5 hôpitaux avec un titre de spécialité clé

Chaque ligne est un hôpital titulaire d'un titre de spécialité clinique clé nationale dans une spécialité à laquelle cette maladie est rattachée. Il s'agit d'un relevé d'inscriptions publiées, non d'une recommandation ni d'un classement.

Hôpital Ville Spécialité (telle que publiée) Preuve Source
West China Hospital, Sichuan University
Tier 3 · LE PLUS ÉLEVÉ
 Chengdu Chirurgie mammaire Niveau A https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Qilu Hospital of Shandong University
Tier 3 · LE PLUS ÉLEVÉ
 Jinan Chirurgie mammaire Niveau A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Shandong Cancer Hospital Jinan Chirurgie mammaire Niveau A https://file.byfy.cn/Resource/File/Upload/file/20251204/20251204085449_9136.pdf
Hubei Cancer Hospital Wuhan Chirurgie mammaire Niveau B https://www.hbch.com.cn/category/1-11.html
Hunan Cancer Hospital
Tier 3 · LE PLUS ÉLEVÉ
 Changsha Chirurgie mammaire Niveau B https://hnca.org.cn/wap/zdks/

5 hôpitaux avec un titre de spécialité clé nationale correspondant.

Les valeurs rédigées en chinois sont citées telles que publiées par la source.

Ce que rapportent les patients

Chiffres agrégés uniquement : un résultat national cité avec sa source et l'année à laquelle il se réfère. Il ne s'agit ni d'un témoignage de patient ni d'une affirmation sur une personne.

  • Selon le rapport de National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) (2023) : National inpatient satisfaction / outpatient satisfaction — 95.42 / 93.95 score, 0-100.

    National aggregate across the 2,168 tertiary public hospitals that took part in the national performance monitoring (all conditions combined; not disease-specific, not hospital-specific).

    Source : National Health Commission - 2023 national tertiary public hospital performance monitoring circular (国卫医政函〔2025〕55 号) — https://www.gov.cn/zhengce/zhengceku/202503/content_7016208.htm — 2023 — Niveau A

Tous les thèmes de thérapie et d'accès

Questions sur cette maladie

Nous ne pouvons pas donner d'avis médical, mais nous pouvons répondre aux questions sur cette page et sur l'organisation d'un traitement en Chine.

Posez-nous une question sur cette pathologie

Codes ICD

Afficher le tableau des codes 10 codes ICD
Version Code Nom dans cette version
ICD-10-WHO C50 Malignant neoplasm of breast
ICD-10-WHO C50.0 Nipple and areola
ICD-10-WHO C50.1 Central portion of breast
ICD-10-WHO C50.2 Upper-inner quadrant of breast
ICD-10-WHO C50.3 Lower-inner quadrant of breast
ICD-10-WHO C50.4 Upper-outer quadrant of breast
ICD-10-WHO C50.5 Lower-outer quadrant of breast
ICD-10-WHO C50.6 Axillary tail of breast
ICD-10-WHO C50.8 Overlapping lesion of breast
ICD-10-WHO C50.9 Breast, unspecified

Les lignes sont les entrées ICD-10 de l'Organisation mondiale de la Santé (OMS) pour cette maladie, citées telles que publiées.

Source et preuve

URL de la source
https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
Schéma de la source
https
Type de source
Commission provinciale de la santé
Niveau de preuve
A - énoncé par une commission de la santé, un institut national de recherche ou une université
Consultée le
2026-09-24